Modality
ADC
MOA
IL-13i
Target
DLL3
Pathway
Hedgehog
PNHPsoriasisGBM
Development Pipeline
Preclinical
~Mar 2022
→ ~Jun 2023
Phase 1
~Sep 2023
→ ~Dec 2024
Phase 2
Mar 2025
→ Jul 2026
Phase 2Current
NCT05741779
1,715 pts·PNH
2025-03→2026-07·Active
1,715 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-07-083mo awayPh2 Data· PNH
Trial Timeline
Q2Q3Q42026Q2Q3
P2
Active
Catalysts
Ph2 Data
2026-07-08 · 3mo away
PNH
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05741779 | Phase 2 | PNH | Active | 1715 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 |